3,892 Shares in Eli Lilly and Company $LLY Purchased by NBH Bank

Key Points

• NBH Bank acquired 3,892 Eli Lilly shares worth approximately $4.67 million in the second quarter, making LLY about 2% of its portfolio and its 11th-largest holding.
• Institutional ownership remains high at 82.53%, with several major investors—including Norges Bank and Bank of America—also establishing or expanding positions.
• Analysts maintain a broadly positive outlook, with a consensus “Moderate Buy” rating and a $1,292.18 price target. Lilly recently exceeded quarterly earnings and revenue expectations, driven by 47.7% year-over-year revenue growth.

NBH Bank acquired a new position in Eli Lilly and Company (NYSE:LLY - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 3,892 shares of the company's stock, valued at approximately $4,668,000. Eli Lilly and Company makes up approximately 2.0% of NBH Bank's investment portfolio, making the stock its 11th biggest position.

Several other institutional investors have also made changes to their positions in LLY. Norges Bank bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $12,976,634,000. Bank of America Corp DE acquired a new position in Eli Lilly and Company during the 2nd quarter worth approximately $13,522,666,000. J. Stern & Co. LLP lifted its stake in Eli Lilly and Company by 46,191.3% in the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company's stock valued at $4,047,245,000 after purchasing an additional 4,038,502 shares during the last quarter. Jupiter Topco LLC acquired a new stake in Eli Lilly and Company in the second quarter valued at approximately $4,667,180,000. Finally, Cardano Risk Management B.V. grew its stake in shares of Eli Lilly and Company by 876.1% during the fourth quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company's stock worth $2,552,419,000 after buying an additional 2,131,734 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

LLY has been the subject of a number of research reports. Morgan Stanley reiterated an "overweight" rating and issued a $1,419.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 6th. Cantor Fitzgerald boosted their price objective on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Jefferies Financial Group upped their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a "buy" rating in a report on Tuesday, June 9th. The Goldman Sachs Group reiterated a "buy" rating and issued a $1,283.00 target price on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Finally, Truist Financial boosted their price target on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a "buy" rating in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $1,292.18.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Large obesity-drug opportunity: J.P. Morgan estimates Eli Lilly could benefit from a roughly $100 billion incretin opportunity. Zepbound and Mounjaro continue to provide substantial growth, while next-generation therapies could extend the company’s expansion beyond its current products. Eli Lilly’s $100B incretin opportunity: Is more upside coming?
• Positive Sentiment: Acquisitions could diversify future growth: Recent deals are being viewed as an effort to build Eli Lilly’s long-term pipeline and reduce reliance on today’s blockbuster GLP-1 medicines. The strategy could support additional revenue streams as the company’s core drugs mature. Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?
• Positive Sentiment: Institutional buying signals confidence: Citadel Advisors and Duquesne Family Office reportedly purchased LLY shares during the second quarter, potentially viewing an earlier pullback as an attractive entry point. Why Billionaires Stanley Druckenmiller and Ken Griffin Are Loading Up on Eli Lilly Stock
• Neutral Sentiment: Analyst and Zacks comparisons portray Lilly as the higher-growth choice versus Johnson & Johnson, but also note that investors must accept greater product-concentration and execution risks. Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?
• Negative Sentiment: Competition and patent limits remain key overhangs: Mounjaro, Zepbound and other leading products face increasing competition, while their patent protection is time-limited. Those concerns may be contributing to caution after the stock’s strong run, particularly given its premium earnings multiple. Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,147.06 on Tuesday. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The firm's fifty day simple moving average is $1,190.13 and its two-hundred day simple moving average is $1,070.66. Eli Lilly and Company has a 12 month low of $712.05 and a 12 month high of $1,292.65. The stock has a market capitalization of $1.08 trillion, a P/E ratio of 38.49, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business's quarterly revenue was up 47.7% on a year-over-year basis. During the same period last year, the company posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, analysts predict that Eli Lilly and Company will post 36.35 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company's payout ratio is 23.22%.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. The trade was a 29.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.